#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=iSGLT2s are a new class of oral hypoglycaemic drugs that block glucose reabsorption at the renal level , thus promoting urine glucose and sodium excretion and reducing plasma glucose levels .
2-1	14-21	iSGLT2s	abstract	new	coref	2-3[3_0]
2-2	22-25	are	_	_	_	_
2-3	26-27	a	abstract[3]	giv[3]	coref	6-6[0_3]
2-4	28-31	new	abstract[3]	giv[3]	_	_
2-5	32-37	class	abstract[3]	giv[3]	_	_
2-6	38-40	of	abstract[3]	giv[3]	_	_
2-7	41-45	oral	abstract[3]|substance[4]	giv[3]|new[4]	coref	8-15[65_4]
2-8	46-59	hypoglycaemic	abstract[3]|substance[4]	giv[3]|new[4]	_	_
2-9	60-65	drugs	abstract[3]|substance[4]	giv[3]|new[4]	_	_
2-10	66-70	that	abstract[3]|substance[4]	giv[3]|new[4]	_	_
2-11	71-76	block	abstract[3]|substance[4]	giv[3]|new[4]	_	_
2-12	77-84	glucose	abstract[3]|substance[4]|substance|abstract[6]	giv[3]|new[4]|new|new[6]	coref	2-21[9_0]
2-13	85-97	reabsorption	abstract[3]|substance[4]|abstract[6]	giv[3]|new[4]|new[6]	_	_
2-14	98-100	at	abstract[3]|substance[4]	giv[3]|new[4]	_	_
2-15	101-104	the	abstract[3]|substance[4]|abstract[7]	giv[3]|new[4]|new[7]	_	_
2-16	105-110	renal	abstract[3]|substance[4]|abstract[7]	giv[3]|new[4]|new[7]	_	_
2-17	111-116	level	abstract[3]|substance[4]|abstract[7]	giv[3]|new[4]|new[7]	_	_
2-18	117-118	,	_	_	_	_
2-19	119-123	thus	_	_	_	_
2-20	124-133	promoting	_	_	_	_
2-21	134-139	urine	substance|substance[9]|substance[10]|abstract[12]	new|giv[9]|new[10]|new[12]	coref|coref	2-28[14_9]|4-17[31_10]
2-22	140-147	glucose	substance[9]|substance[10]|abstract[12]	giv[9]|new[10]|new[12]	_	_
2-23	148-151	and	substance[10]|abstract[12]	new[10]|new[12]	_	_
2-24	152-158	sodium	substance[10]|substance|abstract[12]	new[10]|new|new[12]	_	_
2-25	159-168	excretion	abstract[12]	new[12]	_	_
2-26	169-172	and	_	_	_	_
2-27	173-181	reducing	_	_	_	_
2-28	182-188	plasma	abstract|substance[14]|abstract[15]	new|giv[14]|new[15]	coref|coref|coref	4-18|4-17[30_14]|4-17[33_15]
2-29	189-196	glucose	substance[14]|abstract[15]	giv[14]|new[15]	_	_
2-30	197-203	levels	abstract[15]	new[15]	_	_
2-31	204-205	.	_	_	_	_

#Text=In the present study , we have focused on the effects of empagliflozin on oxidative stress in the leukocytes of T2D subjects , and on inflammatory parameters .
3-1	206-208	In	_	_	_	_
3-2	209-212	the	abstract[16]	new[16]	coref	9-11[71_16]
3-3	213-220	present	abstract[16]	new[16]	_	_
3-4	221-226	study	abstract[16]	new[16]	_	_
3-5	227-228	,	_	_	_	_
3-6	229-231	we	person	acc	ana	4-24
3-7	232-236	have	_	_	_	_
3-8	237-244	focused	_	_	_	_
3-9	245-247	on	_	_	_	_
3-10	248-251	the	abstract[18]	new[18]	coref	11-16[92_18]
3-11	252-259	effects	abstract[18]	new[18]	_	_
3-12	260-262	of	abstract[18]	new[18]	_	_
3-13	263-276	empagliflozin	abstract[18]|substance[19]	new[18]|new[19]	coref	4-38[41_19]
3-14	277-279	on	abstract[18]|substance[19]	new[18]|new[19]	_	_
3-15	280-289	oxidative	abstract[18]|substance[19]|abstract[20]	new[18]|new[19]|new[20]	coref	14-26[128_20]
3-16	290-296	stress	abstract[18]|substance[19]|abstract[20]	new[18]|new[19]|new[20]	_	_
3-17	297-299	in	abstract[18]|substance[19]|abstract[20]	new[18]|new[19]|new[20]	_	_
3-18	300-303	the	abstract[18]|substance[19]|abstract[20]|abstract[21]	new[18]|new[19]|new[20]|new[21]	_	_
3-19	304-314	leukocytes	abstract[18]|substance[19]|abstract[20]|abstract[21]	new[18]|new[19]|new[20]|new[21]	_	_
3-20	315-317	of	abstract[18]|substance[19]|abstract[20]|abstract[21]	new[18]|new[19]|new[20]|new[21]	_	_
3-21	318-321	T2D	abstract[18]|substance[19]|abstract[20]|abstract[21]|abstract|animal[23]	new[18]|new[19]|new[20]|new[21]|new|new[23]	coref	13-17
3-22	322-330	subjects	abstract[18]|substance[19]|abstract[20]|abstract[21]|animal[23]	new[18]|new[19]|new[20]|new[21]|new[23]	_	_
3-23	331-332	,	_	_	_	_
3-24	333-336	and	_	_	_	_
3-25	337-339	on	_	_	_	_
3-26	340-352	inflammatory	abstract[24]	new[24]	coref	5-7[44_24]
3-27	353-363	parameters	abstract[24]	new[24]	_	_
3-28	364-365	.	_	_	_	_

#Text=In addition to a reduction in body weight and an improved metabolic profile — characterized by reduced plasma glucose and HbA1c levels — we observed a reduction in mitochondrial superoxide production in diabetic patients after treatment with the iSGLT2 empagliflozin , together with increased antioxidant defenses .
4-1	366-368	In	_	_	_	_
4-2	369-377	addition	_	_	_	_
4-3	378-380	to	_	_	_	_
4-4	381-382	a	abstract[25]	new[25]	coref	4-26[35_25]
4-5	383-392	reduction	abstract[25]	new[25]	_	_
4-6	393-395	in	abstract[25]	new[25]	_	_
4-7	396-400	body	abstract[25]|object|abstract[27]	new[25]|new|new[27]	coref|coref	11-22|11-22[95_27]
4-8	401-407	weight	abstract[25]|abstract[27]	new[25]|new[27]	_	_
4-9	408-411	and	_	_	_	_
4-10	412-414	an	abstract[28]	new[28]	coref	6-10[54_28]
4-11	415-423	improved	abstract[28]	new[28]	_	_
4-12	424-433	metabolic	abstract[28]	new[28]	_	_
4-13	434-441	profile	abstract[28]	new[28]	_	_
4-14	442-443	—	abstract[28]	new[28]	_	_
4-15	444-457	characterized	abstract[28]	new[28]	_	_
4-16	458-460	by	abstract[28]	new[28]	_	_
4-17	461-468	reduced	abstract[28]|substance[30]|substance[31]|abstract[33]	new[28]|giv[30]|giv[31]|giv[33]	_	_
4-18	469-475	plasma	abstract[28]|abstract|substance[30]|substance[31]|abstract[33]	new[28]|giv|giv[30]|giv[31]|giv[33]	coref	21-6
4-19	476-483	glucose	abstract[28]|substance[30]|substance[31]|abstract[33]	new[28]|giv[30]|giv[31]|giv[33]	_	_
4-20	484-487	and	abstract[28]|substance[31]|abstract[33]	new[28]|giv[31]|giv[33]	_	_
4-21	488-493	HbA1c	abstract[28]|substance[31]|abstract|abstract[33]	new[28]|giv[31]|new|giv[33]	coref	10-7
4-22	494-500	levels	abstract[28]|abstract[33]	new[28]|giv[33]	_	_
4-23	501-502	—	_	_	_	_
4-24	503-505	we	person	giv	ana	7-19
4-25	506-514	observed	_	_	_	_
4-26	515-516	a	abstract[35]	giv[35]	coref	9-17[72_35]
4-27	517-526	reduction	abstract[35]	giv[35]	_	_
4-28	527-529	in	abstract[35]	giv[35]	_	_
4-29	530-543	mitochondrial	abstract[35]|abstract[37]	giv[35]|new[37]	coref	16-5[143_37]
4-30	544-554	superoxide	abstract[35]|substance|abstract[37]	giv[35]|new|new[37]	coref	19-15
4-31	555-565	production	abstract[35]|abstract[37]	giv[35]|new[37]	_	_
4-32	566-568	in	abstract[35]|abstract[37]	giv[35]|new[37]	_	_
4-33	569-577	diabetic	abstract[35]|abstract[37]|person[38]	giv[35]|new[37]|new[38]	coref	13-17[116_38]
4-34	578-586	patients	abstract[35]|abstract[37]|person[38]	giv[35]|new[37]|new[38]	_	_
4-35	587-592	after	_	_	_	_
4-36	593-602	treatment	abstract[39]	new[39]	coref	5-16[46_39]
4-37	603-607	with	abstract[39]	new[39]	_	_
4-38	608-611	the	abstract[39]|substance[41]	new[39]|giv[41]	coref	5-18[0_41]
4-39	612-618	iSGLT2	abstract[39]|abstract|substance[41]	new[39]|new|giv[41]	coref	11-11
4-40	619-632	empagliflozin	abstract[39]|substance[41]	new[39]|giv[41]	_	_
4-41	633-634	,	_	_	_	_
4-42	635-643	together	abstract[42]	new[42]	coref	15-5[132_42]
4-43	644-648	with	abstract[42]	new[42]	_	_
4-44	649-658	increased	abstract[42]	new[42]	_	_
4-45	659-670	antioxidant	abstract[42]	new[42]	_	_
4-46	671-679	defenses	abstract[42]	new[42]	_	_
4-47	680-681	.	_	_	_	_

#Text=Moreover , reduced proinflammatory markers and increased anti-inflammatory parameters were maintained after 24 weeks of treatment with empagliflozin .
5-1	682-690	Moreover	_	_	_	_
5-2	691-692	,	_	_	_	_
5-3	693-700	reduced	abstract[43]	new[43]	_	_
5-4	701-716	proinflammatory	abstract[43]	new[43]	_	_
5-5	717-724	markers	abstract[43]	new[43]	_	_
5-6	725-728	and	_	_	_	_
5-7	729-738	increased	abstract[44]	giv[44]	ana	6-2[0_44]
5-8	739-756	anti-inflammatory	abstract[44]	giv[44]	_	_
5-9	757-767	parameters	abstract[44]	giv[44]	_	_
5-10	768-772	were	_	_	_	_
5-11	773-783	maintained	_	_	_	_
5-12	784-789	after	_	_	_	_
5-13	790-792	24	time[45]	new[45]	_	_
5-14	793-798	weeks	time[45]	new[45]	_	_
5-15	799-801	of	time[45]	new[45]	_	_
5-16	802-811	treatment	time[45]|abstract[46]	new[45]|giv[46]	coref	7-1[56_46]
5-17	812-816	with	time[45]|abstract[46]	new[45]|giv[46]	_	_
5-18	817-830	empagliflozin	time[45]|abstract[46]|substance	new[45]|giv[46]|giv	coref	7-1
5-19	831-832	.	_	_	_	_

#Text=Besides their glucose-lowering effect , iSGLT2s produce changes in the lipid profile that should also be highlighted .
6-1	833-840	Besides	_	_	_	_
6-2	841-846	their	abstract|abstract[50]	giv|new[50]	coref	18-11[165_50]
6-3	847-863	glucose-lowering	substance|abstract[50]	new|new[50]	_	_
6-4	864-870	effect	abstract[50]	new[50]	_	_
6-5	871-872	,	_	_	_	_
6-6	873-880	iSGLT2s	abstract	giv	coref	8-11
6-7	881-888	produce	_	_	_	_
6-8	889-896	changes	abstract[52]	new[52]	coref	21-3[191_52]
6-9	897-899	in	abstract[52]	new[52]	_	_
6-10	900-903	the	abstract[52]|abstract[54]	new[52]|giv[54]	_	_
6-11	904-909	lipid	abstract[52]|substance|abstract[54]	new[52]|new|giv[54]	_	_
6-12	910-917	profile	abstract[52]|abstract[54]	new[52]|giv[54]	_	_
6-13	918-922	that	abstract[52]	new[52]	_	_
6-14	923-929	should	abstract[52]	new[52]	_	_
6-15	930-934	also	abstract[52]	new[52]	_	_
6-16	935-937	be	abstract[52]	new[52]	_	_
6-17	938-949	highlighted	abstract[52]	new[52]	_	_
6-18	950-951	.	_	_	_	_

#Text=Empagliflozin treatment is correlated with increased total cholesterol due to slight increases in HDL-c and LDL-c , as we have observed , and reported in other studies .
7-1	952-965	Empagliflozin	substance|abstract[56]	giv|giv[56]	coref|coref	9-29|11-9[89_56]
7-2	966-975	treatment	abstract[56]	giv[56]	_	_
7-3	976-978	is	_	_	_	_
7-4	979-989	correlated	_	_	_	_
7-5	990-994	with	_	_	_	_
7-6	995-1004	increased	substance[57]	new[57]	_	_
7-7	1005-1010	total	substance[57]	new[57]	_	_
7-8	1011-1022	cholesterol	substance[57]	new[57]	_	_
7-9	1023-1026	due	substance[57]	new[57]	_	_
7-10	1027-1029	to	substance[57]	new[57]	_	_
7-11	1030-1036	slight	substance[57]|event[58]	new[57]|new[58]	_	_
7-12	1037-1046	increases	substance[57]|event[58]	new[57]|new[58]	_	_
7-13	1047-1049	in	substance[57]|event[58]	new[57]|new[58]	_	_
7-14	1050-1055	HDL-c	substance[57]|event[58]|abstract	new[57]|new[58]|new	_	_
7-15	1056-1059	and	substance[57]|event[58]	new[57]|new[58]	_	_
7-16	1060-1065	LDL-c	substance[57]|event[58]|abstract	new[57]|new[58]|new	_	_
7-17	1066-1067	,	_	_	_	_
7-18	1068-1070	as	_	_	_	_
7-19	1071-1073	we	person	giv	ana	19-1
7-20	1074-1078	have	_	_	_	_
7-21	1079-1087	observed	_	_	_	_
7-22	1088-1089	,	_	_	_	_
7-23	1090-1093	and	_	_	_	_
7-24	1094-1102	reported	_	_	_	_
7-25	1103-1105	in	_	_	_	_
7-26	1106-1111	other	abstract[62]	new[62]	coref	9-6[68_62]
7-27	1112-1119	studies	abstract[62]	new[62]	_	_
7-28	1120-1121	.	_	_	_	_

#Text=However , there is a well-documented cardiovascular protection exerted by iSGLT2s , which endows these drugs with clinical potential .
8-1	1122-1129	However	_	_	_	_
8-2	1130-1131	,	_	_	_	_
8-3	1132-1137	there	_	_	_	_
8-4	1138-1140	is	_	_	_	_
8-5	1141-1142	a	abstract[63]	new[63]	coref	10-34[86_63]
8-6	1143-1158	well-documented	abstract[63]	new[63]	_	_
8-7	1159-1173	cardiovascular	abstract[63]	new[63]	_	_
8-8	1174-1184	protection	abstract[63]	new[63]	_	_
8-9	1185-1192	exerted	abstract[63]	new[63]	_	_
8-10	1193-1195	by	abstract[63]	new[63]	_	_
8-11	1196-1203	iSGLT2s	abstract[63]|abstract	new[63]|giv	_	_
8-12	1204-1205	,	abstract[63]	new[63]	_	_
8-13	1206-1211	which	abstract[63]	new[63]	_	_
8-14	1212-1218	endows	abstract[63]	new[63]	_	_
8-15	1219-1224	these	abstract[63]|substance[65]	new[63]|giv[65]	_	_
8-16	1225-1230	drugs	abstract[63]|substance[65]	new[63]|giv[65]	_	_
8-17	1231-1235	with	abstract[63]	new[63]	_	_
8-18	1236-1244	clinical	abstract[63]|abstract[66]	new[63]|new[66]	ana	9-1[0_66]
8-19	1245-1254	potential	abstract[63]|abstract[66]	new[63]|new[66]	_	_
8-20	1255-1256	.	_	_	_	_

#Text=This has been reflected by several studies , such as the EMPA-REG OUTCOME study in which a reduction of 38 % in cardiovascular mortality was evident in the empagliflozin vs. placebo group .
9-1	1257-1261	This	abstract	giv	_	_
9-2	1262-1265	has	_	_	_	_
9-3	1266-1270	been	_	_	_	_
9-4	1271-1280	reflected	_	_	_	_
9-5	1281-1283	by	_	_	_	_
9-6	1284-1291	several	abstract[68]	giv[68]	coref	17-21[161_68]
9-7	1292-1299	studies	abstract[68]	giv[68]	_	_
9-8	1300-1301	,	abstract[68]	giv[68]	_	_
9-9	1302-1306	such	abstract[68]	giv[68]	_	_
9-10	1307-1309	as	abstract[68]	giv[68]	_	_
9-11	1310-1313	the	abstract[68]|abstract[71]	giv[68]|giv[71]	coref	10-10[80_71]
9-12	1314-1322	EMPA-REG	abstract[68]|abstract|abstract[71]	giv[68]|new|giv[71]	coref	12-21
9-13	1323-1330	OUTCOME	abstract[68]|abstract|abstract[71]	giv[68]|new|giv[71]	coref	12-22
9-14	1331-1336	study	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
9-15	1337-1339	in	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
9-16	1340-1345	which	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
9-17	1346-1347	a	abstract[68]|abstract[71]|abstract[72]	giv[68]|giv[71]|giv[72]	coref	10-3[78_72]
9-18	1348-1357	reduction	abstract[68]|abstract[71]|abstract[72]	giv[68]|giv[71]|giv[72]	_	_
9-19	1358-1360	of	abstract[68]|abstract[71]|abstract[72]	giv[68]|giv[71]|giv[72]	_	_
9-20	1361-1363	38	abstract[68]|abstract[71]|abstract[72]|abstract[73]	giv[68]|giv[71]|giv[72]|new[73]	_	_
9-21	1364-1365	%	abstract[68]|abstract[71]|abstract[72]|abstract[73]	giv[68]|giv[71]|giv[72]|new[73]	_	_
9-22	1366-1368	in	abstract[68]|abstract[71]|abstract[72]|abstract[73]	giv[68]|giv[71]|giv[72]|new[73]	_	_
9-23	1369-1383	cardiovascular	abstract[68]|abstract[71]|abstract[72]|abstract[73]|abstract[74]	giv[68]|giv[71]|giv[72]|new[73]|new[74]	coref	10-38[87_74]
9-24	1384-1393	mortality	abstract[68]|abstract[71]|abstract[72]|abstract[73]|abstract[74]	giv[68]|giv[71]|giv[72]|new[73]|new[74]	_	_
9-25	1394-1397	was	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
9-26	1398-1405	evident	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
9-27	1406-1408	in	abstract[68]|abstract[71]	giv[68]|giv[71]	_	_
9-28	1409-1412	the	abstract[68]|abstract[71]|animal[77]	giv[68]|giv[71]|new[77]	coref	12-14[104_77]
9-29	1413-1426	empagliflozin	abstract[68]|abstract[71]|substance|animal[77]	giv[68]|giv[71]|giv|new[77]	coref	12-18
9-30	1427-1430	vs.	abstract[68]|abstract[71]|animal[77]	giv[68]|giv[71]|new[77]	_	_
9-31	1431-1438	placebo	abstract[68]|abstract[71]|substance|animal[77]	giv[68]|giv[71]|new|new[77]	_	_
9-32	1439-1444	group	abstract[68]|abstract[71]|animal[77]	giv[68]|giv[71]|new[77]	_	_
9-33	1445-1446	.	_	_	_	_

#Text=However , neither the reduction in HbA1c observed in the study ( 0.60 % over 12 weeks ) nor the reduction in SBP ( up to 5 mmHg ) are sufficient to explain the reported protection against cardiovascular mortality .
10-1	1447-1454	However	_	_	_	_
10-2	1455-1456	,	_	_	_	_
10-3	1457-1464	neither	abstract[78]	giv[78]	appos	10-13[81_78]
10-4	1465-1468	the	abstract[78]	giv[78]	_	_
10-5	1469-1478	reduction	abstract[78]	giv[78]	_	_
10-6	1479-1481	in	abstract[78]	giv[78]	_	_
10-7	1482-1487	HbA1c	abstract[78]|abstract	giv[78]|giv	coref	11-20
10-8	1488-1496	observed	abstract[78]	giv[78]	_	_
10-9	1497-1499	in	abstract[78]	giv[78]	_	_
10-10	1500-1503	the	abstract[78]|abstract[80]	giv[78]|giv[80]	coref	12-20[108_80]
10-11	1504-1509	study	abstract[78]|abstract[80]	giv[78]|giv[80]	_	_
10-12	1510-1511	(	_	_	_	_
10-13	1512-1516	0.60	abstract[81]	giv[81]	coref	10-20[83_81]
10-14	1517-1518	%	abstract[81]	giv[81]	_	_
10-15	1519-1523	over	abstract[81]	giv[81]	_	_
10-16	1524-1526	12	abstract[81]|time[82]	giv[81]|new[82]	_	_
10-17	1527-1532	weeks	abstract[81]|time[82]	giv[81]|new[82]	_	_
10-18	1533-1534	)	_	_	_	_
10-19	1535-1538	nor	_	_	_	_
10-20	1539-1542	the	abstract[83]	giv[83]	appos	10-25[85_83]
10-21	1543-1552	reduction	abstract[83]	giv[83]	_	_
10-22	1553-1555	in	abstract[83]	giv[83]	_	_
10-23	1556-1559	SBP	abstract[83]|abstract	giv[83]|new	_	_
10-24	1560-1561	(	_	_	_	_
10-25	1562-1564	up	abstract[85]	giv[85]	coref	12-5[99_85]
10-26	1565-1567	to	abstract[85]	giv[85]	_	_
10-27	1568-1569	5	abstract[85]	giv[85]	_	_
10-28	1570-1574	mmHg	abstract[85]	giv[85]	_	_
10-29	1575-1576	)	_	_	_	_
10-30	1577-1580	are	_	_	_	_
10-31	1581-1591	sufficient	_	_	_	_
10-32	1592-1594	to	_	_	_	_
10-33	1595-1602	explain	_	_	_	_
10-34	1603-1606	the	abstract[86]	giv[86]	coref	14-12[123_86]
10-35	1607-1615	reported	abstract[86]	giv[86]	_	_
10-36	1616-1626	protection	abstract[86]	giv[86]	_	_
10-37	1627-1634	against	abstract[86]	giv[86]	_	_
10-38	1635-1649	cardiovascular	abstract[86]|abstract[87]	giv[86]|giv[87]	_	_
10-39	1650-1659	mortality	abstract[86]|abstract[87]	giv[86]|giv[87]	_	_
10-40	1660-1661	.	_	_	_	_

#Text=Interestingly , as little as 24 weeks of treatment with iSGLT2 is sufficient to witness their beneficial effects on HbA1c , body weight , blood pressure and , most importantly , on the cardiovascular system .
11-1	1662-1675	Interestingly	_	_	_	_
11-2	1676-1677	,	_	_	_	_
11-3	1678-1680	as	time[88]	new[88]	ana	11-16[0_88]
11-4	1681-1687	little	time[88]	new[88]	_	_
11-5	1688-1690	as	time[88]	new[88]	_	_
11-6	1691-1693	24	time[88]	new[88]	_	_
11-7	1694-1699	weeks	time[88]	new[88]	_	_
11-8	1700-1702	of	time[88]	new[88]	_	_
11-9	1703-1712	treatment	time[88]|abstract[89]	new[88]|giv[89]	coref	13-13[113_89]
11-10	1713-1717	with	time[88]|abstract[89]	new[88]|giv[89]	_	_
11-11	1718-1724	iSGLT2	time[88]|abstract[89]|abstract	new[88]|giv[89]|giv	coref	14-17
11-12	1725-1727	is	_	_	_	_
11-13	1728-1738	sufficient	_	_	_	_
11-14	1739-1741	to	_	_	_	_
11-15	1742-1749	witness	_	_	_	_
11-16	1750-1755	their	time|abstract[92]	giv|giv[92]	_	_
11-17	1756-1766	beneficial	abstract[92]	giv[92]	_	_
11-18	1767-1774	effects	abstract[92]	giv[92]	_	_
11-19	1775-1777	on	abstract[92]	giv[92]	_	_
11-20	1778-1783	HbA1c	abstract[92]|abstract	giv[92]|giv	_	_
11-21	1784-1785	,	abstract[92]	giv[92]	_	_
11-22	1786-1790	body	abstract[92]|object|abstract[95]	giv[92]|giv|giv[95]	_	_
11-23	1791-1797	weight	abstract[92]|abstract[95]	giv[92]|giv[95]	_	_
11-24	1798-1799	,	abstract[92]	giv[92]	_	_
11-25	1800-1805	blood	abstract[92]|abstract[96]	giv[92]|new[96]	_	_
11-26	1806-1814	pressure	abstract[92]|abstract[96]	giv[92]|new[96]	_	_
11-27	1815-1818	and	_	_	_	_
11-28	1819-1820	,	_	_	_	_
11-29	1821-1825	most	abstract[97]	new[97]	coref	16-11[146_97]
11-30	1826-1837	importantly	abstract[97]	new[97]	_	_
11-31	1838-1839	,	abstract[97]	new[97]	_	_
11-32	1840-1842	on	abstract[97]	new[97]	_	_
11-33	1843-1846	the	abstract[97]	new[97]	_	_
11-34	1847-1861	cardiovascular	abstract[97]	new[97]	_	_
11-35	1862-1868	system	abstract[97]	new[97]	_	_
11-36	1869-1870	.	_	_	_	_

#Text=As an example , the reduction in hospitalization rates for heart failure in the group treated with empagliflozin in the EMPA-REG OUTCOME study was already significant at this time point .
12-1	1871-1873	As	_	_	_	_
12-2	1874-1876	an	abstract[98]	new[98]	_	_
12-3	1877-1884	example	abstract[98]	new[98]	_	_
12-4	1885-1886	,	_	_	_	_
12-5	1887-1890	the	abstract[99]	giv[99]	_	_
12-6	1891-1900	reduction	abstract[99]	giv[99]	_	_
12-7	1901-1903	in	abstract[99]	giv[99]	_	_
12-8	1904-1919	hospitalization	abstract[99]|abstract|abstract[101]	giv[99]|new|new[101]	_	_
12-9	1920-1925	rates	abstract[99]|abstract[101]	giv[99]|new[101]	_	_
12-10	1926-1929	for	abstract[99]|abstract[101]	giv[99]|new[101]	_	_
12-11	1930-1935	heart	abstract[99]|abstract[101]|object|event[103]	giv[99]|new[101]|new|new[103]	_	_
12-12	1936-1943	failure	abstract[99]|abstract[101]|event[103]	giv[99]|new[101]|new[103]	_	_
12-13	1944-1946	in	abstract[99]|abstract[101]	giv[99]|new[101]	_	_
12-14	1947-1950	the	abstract[99]|abstract[101]|animal[104]	giv[99]|new[101]|giv[104]	_	_
12-15	1951-1956	group	abstract[99]|abstract[101]|animal[104]	giv[99]|new[101]|giv[104]	_	_
12-16	1957-1964	treated	abstract[99]|abstract[101]|animal[104]	giv[99]|new[101]|giv[104]	_	_
12-17	1965-1969	with	abstract[99]|abstract[101]|animal[104]	giv[99]|new[101]|giv[104]	_	_
12-18	1970-1983	empagliflozin	abstract[99]|abstract[101]|animal[104]|substance	giv[99]|new[101]|giv[104]|giv	coref	13-15[114_0]
12-19	1984-1986	in	abstract[99]|abstract[101]|animal[104]	giv[99]|new[101]|giv[104]	_	_
12-20	1987-1990	the	abstract[99]|abstract[101]|animal[104]|abstract[108]	giv[99]|new[101]|giv[104]|giv[108]	coref	13-1[110_108]
12-21	1991-1999	EMPA-REG	abstract[99]|abstract[101]|animal[104]|abstract|abstract[108]	giv[99]|new[101]|giv[104]|giv|giv[108]	_	_
12-22	2000-2007	OUTCOME	abstract[99]|abstract[101]|animal[104]|abstract|abstract[108]	giv[99]|new[101]|giv[104]|giv|giv[108]	_	_
12-23	2008-2013	study	abstract[99]|abstract[101]|animal[104]|abstract[108]	giv[99]|new[101]|giv[104]|giv[108]	_	_
12-24	2014-2017	was	_	_	_	_
12-25	2018-2025	already	_	_	_	_
12-26	2026-2037	significant	_	_	_	_
12-27	2038-2040	at	_	_	_	_
12-28	2041-2045	this	time[109]	new[109]	_	_
12-29	2046-2050	time	time[109]	new[109]	_	_
12-30	2051-2056	point	time[109]	new[109]	_	_
12-31	2057-2058	.	_	_	_	_

#Text=A recent study demonstrated an improved arterial stiffness after 6 weeks of treatment with empagliflozin in T2D patients , and hs-CRP was shown to be one of the main significant determinants for this improvement .
13-1	2059-2060	A	abstract[110]	giv[110]	_	_
13-2	2061-2067	recent	abstract[110]	giv[110]	_	_
13-3	2068-2073	study	abstract[110]	giv[110]	_	_
13-4	2074-2086	demonstrated	_	_	_	_
13-5	2087-2089	an	abstract[111]	new[111]	_	_
13-6	2090-2098	improved	abstract[111]	new[111]	_	_
13-7	2099-2107	arterial	abstract[111]	new[111]	_	_
13-8	2108-2117	stiffness	abstract[111]	new[111]	_	_
13-9	2118-2123	after	_	_	_	_
13-10	2124-2125	6	time[112]	new[112]	_	_
13-11	2126-2131	weeks	time[112]	new[112]	_	_
13-12	2132-2134	of	time[112]	new[112]	_	_
13-13	2135-2144	treatment	time[112]|abstract[113]	new[112]|giv[113]	coref	14-17[125_113]
13-14	2145-2149	with	time[112]|abstract[113]	new[112]|giv[113]	_	_
13-15	2150-2163	empagliflozin	time[112]|abstract[113]|substance[114]	new[112]|giv[113]|giv[114]	coref	21-13[0_114]
13-16	2164-2166	in	time[112]|abstract[113]|substance[114]	new[112]|giv[113]|giv[114]	_	_
13-17	2167-2170	T2D	time[112]|abstract[113]|substance[114]|abstract|person[116]	new[112]|giv[113]|giv[114]|giv|giv[116]	coref|coref	15-30|19-5[174_116]
13-18	2171-2179	patients	time[112]|abstract[113]|substance[114]|person[116]	new[112]|giv[113]|giv[114]|giv[116]	_	_
13-19	2180-2181	,	_	_	_	_
13-20	2182-2185	and	_	_	_	_
13-21	2186-2192	hs-CRP	abstract	new	_	_
13-22	2193-2196	was	_	_	_	_
13-23	2197-2202	shown	_	_	_	_
13-24	2203-2205	to	_	_	_	_
13-25	2206-2208	be	_	_	_	_
13-26	2209-2212	one	abstract[118]	new[118]	_	_
13-27	2213-2215	of	abstract[118]	new[118]	_	_
13-28	2216-2219	the	abstract[118]|abstract[119]	new[118]|new[119]	_	_
13-29	2220-2224	main	abstract[118]|abstract[119]	new[118]|new[119]	_	_
13-30	2225-2236	significant	abstract[118]|abstract[119]	new[118]|new[119]	_	_
13-31	2237-2249	determinants	abstract[118]|abstract[119]	new[118]|new[119]	_	_
13-32	2250-2253	for	abstract[118]|abstract[119]	new[118]|new[119]	_	_
13-33	2254-2258	this	abstract[118]|abstract[119]|event[120]	new[118]|new[119]|new[120]	_	_
13-34	2259-2270	improvement	abstract[118]|abstract[119]|event[120]	new[118]|new[119]|new[120]	_	_
13-35	2271-2272	.	_	_	_	_

#Text=Nevertheless , despite the available evidence , the molecular mechanisms underlying the cardiovascular protection attributable to iSGLT2 treatment are still unknown , though amelioration of oxidative stress has been hypothesized to be a potential contributor .
14-1	2273-2285	Nevertheless	_	_	_	_
14-2	2286-2287	,	_	_	_	_
14-3	2288-2295	despite	_	_	_	_
14-4	2296-2299	the	abstract[121]	new[121]	_	_
14-5	2300-2309	available	abstract[121]	new[121]	_	_
14-6	2310-2318	evidence	abstract[121]	new[121]	_	_
14-7	2319-2320	,	_	_	_	_
14-8	2321-2324	the	abstract[122]	new[122]	_	_
14-9	2325-2334	molecular	abstract[122]	new[122]	_	_
14-10	2335-2345	mechanisms	abstract[122]	new[122]	_	_
14-11	2346-2356	underlying	abstract[122]	new[122]	_	_
14-12	2357-2360	the	abstract[122]|abstract[123]	new[122]|giv[123]	coref	15-22[137_123]
14-13	2361-2375	cardiovascular	abstract[122]|abstract[123]	new[122]|giv[123]	_	_
14-14	2376-2386	protection	abstract[122]|abstract[123]	new[122]|giv[123]	_	_
14-15	2387-2399	attributable	abstract[122]|abstract[123]	new[122]|giv[123]	_	_
14-16	2400-2402	to	abstract[122]|abstract[123]	new[122]|giv[123]	_	_
14-17	2403-2409	iSGLT2	abstract[122]|abstract[123]|abstract|abstract[125]	new[122]|giv[123]|giv|giv[125]	coref|coref	18-14|19-8[176_125]
14-18	2410-2419	treatment	abstract[122]|abstract[123]|abstract[125]	new[122]|giv[123]|giv[125]	_	_
14-19	2420-2423	are	_	_	_	_
14-20	2424-2429	still	_	_	_	_
14-21	2430-2437	unknown	_	_	_	_
14-22	2438-2439	,	_	_	_	_
14-23	2440-2446	though	_	_	_	_
14-24	2447-2459	amelioration	abstract[126]	new[126]	_	_
14-25	2460-2462	of	abstract[126]	new[126]	_	_
14-26	2463-2472	oxidative	abstract[126]|abstract|abstract[128]	new[126]|new|giv[128]	coref|coref	16-1|16-1[142_128]
14-27	2473-2479	stress	abstract[126]|abstract[128]	new[126]|giv[128]	_	_
14-28	2480-2483	has	_	_	_	_
14-29	2484-2488	been	_	_	_	_
14-30	2489-2501	hypothesized	_	_	_	_
14-31	2502-2504	to	_	_	_	_
14-32	2505-2507	be	_	_	_	_
14-33	2508-2509	a	abstract[129]	new[129]	_	_
14-34	2510-2519	potential	abstract[129]	new[129]	_	_
14-35	2520-2531	contributor	abstract[129]	new[129]	_	_
14-36	2532-2533	.	_	_	_	_

#Text=Because cardiac tissue possesses low antioxidant defenses , increasing the expression or activity of antioxidant enzymes could be a mechanism of cardiac protection under high risk situations such as T2D .
15-1	2534-2541	Because	_	_	_	_
15-2	2542-2549	cardiac	object[130]	new[130]	coref	24-24[226_130]
15-3	2550-2556	tissue	object[130]	new[130]	_	_
15-4	2557-2566	possesses	_	_	_	_
15-5	2567-2570	low	abstract[132]	giv[132]	_	_
15-6	2571-2582	antioxidant	abstract|abstract[132]	new|giv[132]	coref	20-9
15-7	2583-2591	defenses	abstract[132]	giv[132]	_	_
15-8	2592-2593	,	_	_	_	_
15-9	2594-2604	increasing	_	_	_	_
15-10	2605-2608	the	abstract[133]	new[133]	coref	20-5[186_133]
15-11	2609-2619	expression	abstract[133]	new[133]	_	_
15-12	2620-2622	or	_	_	_	_
15-13	2623-2631	activity	abstract[134]	new[134]	coref	23-22[213_134]
15-14	2632-2634	of	abstract[134]	new[134]	_	_
15-15	2635-2646	antioxidant	abstract[134]|substance[135]	new[134]|new[135]	coref	20-8[188_135]
15-16	2647-2654	enzymes	abstract[134]|substance[135]	new[134]|new[135]	_	_
15-17	2655-2660	could	_	_	_	_
15-18	2661-2663	be	_	_	_	_
15-19	2664-2665	a	abstract[136]	new[136]	_	_
15-20	2666-2675	mechanism	abstract[136]	new[136]	_	_
15-21	2676-2678	of	abstract[136]	new[136]	_	_
15-22	2679-2686	cardiac	abstract[136]|abstract[137]	new[136]|giv[137]	_	_
15-23	2687-2697	protection	abstract[136]|abstract[137]	new[136]|giv[137]	_	_
15-24	2698-2703	under	abstract[136]|abstract[137]	new[136]|giv[137]	_	_
15-25	2704-2708	high	abstract[136]|abstract[137]|abstract[138]|abstract[139]	new[136]|giv[137]|new[138]|new[139]	_	_
15-26	2709-2713	risk	abstract[136]|abstract[137]|abstract[138]|abstract[139]	new[136]|giv[137]|new[138]|new[139]	_	_
15-27	2714-2724	situations	abstract[136]|abstract[137]|abstract[139]	new[136]|giv[137]|new[139]	_	_
15-28	2725-2729	such	abstract[136]|abstract[137]|abstract[139]	new[136]|giv[137]|new[139]	_	_
15-29	2730-2732	as	abstract[136]|abstract[137]|abstract[139]	new[136]|giv[137]|new[139]	_	_
15-30	2733-2736	T2D	abstract[136]|abstract[137]|abstract[139]|abstract	new[136]|giv[137]|new[139]|giv	coref	19-5
15-31	2737-2738	.	_	_	_	_

#Text=Oxidative stress occurs when the production of pro-oxidant species overcomes the intrinsic antioxidant defense system of the cell , thus triggering damage to lipids , proteins and DNA , and eventually compromising cellular and tissue function .
16-1	2739-2748	Oxidative	abstract|abstract[142]	giv|giv[142]	coref|coref	17-13[158_142]|18-16
16-2	2749-2755	stress	abstract[142]	giv[142]	_	_
16-3	2756-2762	occurs	_	_	_	_
16-4	2763-2767	when	_	_	_	_
16-5	2768-2771	the	abstract[143]	giv[143]	coref	19-14[179_143]
16-6	2772-2782	production	abstract[143]	giv[143]	_	_
16-7	2783-2785	of	abstract[143]	giv[143]	_	_
16-8	2786-2797	pro-oxidant	abstract[143]|plant[144]	giv[143]|new[144]	_	_
16-9	2798-2805	species	abstract[143]|plant[144]	giv[143]|new[144]	_	_
16-10	2806-2815	overcomes	_	_	_	_
16-11	2816-2819	the	abstract[146]	giv[146]	_	_
16-12	2820-2829	intrinsic	abstract[146]	giv[146]	_	_
16-13	2830-2841	antioxidant	abstract[145]|abstract[146]	new[145]|giv[146]	_	_
16-14	2842-2849	defense	abstract[145]|abstract[146]	new[145]|giv[146]	_	_
16-15	2850-2856	system	abstract[146]	giv[146]	_	_
16-16	2857-2859	of	abstract[146]	giv[146]	_	_
16-17	2860-2863	the	abstract[146]|place[147]	giv[146]|new[147]	_	_
16-18	2864-2868	cell	abstract[146]|place[147]	giv[146]|new[147]	_	_
16-19	2869-2870	,	_	_	_	_
16-20	2871-2875	thus	_	_	_	_
16-21	2876-2886	triggering	_	_	_	_
16-22	2887-2893	damage	abstract[148]	new[148]	_	_
16-23	2894-2896	to	abstract[148]	new[148]	_	_
16-24	2897-2903	lipids	abstract[148]|substance	new[148]|new	_	_
16-25	2904-2905	,	abstract[148]	new[148]	_	_
16-26	2906-2914	proteins	abstract[148]|substance	new[148]|new	_	_
16-27	2915-2918	and	abstract[148]	new[148]	_	_
16-28	2919-2922	DNA	abstract[148]|substance	new[148]|new	_	_
16-29	2923-2924	,	_	_	_	_
16-30	2925-2928	and	_	_	_	_
16-31	2929-2939	eventually	_	_	_	_
16-32	2940-2952	compromising	_	_	_	_
16-33	2953-2961	cellular	abstract[152]	new[152]	_	_
16-34	2962-2965	and	abstract[152]	new[152]	_	_
16-35	2966-2972	tissue	abstract[152]	new[152]	_	_
16-36	2973-2981	function	abstract[152]	new[152]	_	_
16-37	2982-2983	.	_	_	_	_

#Text=Exploring the role of SGLT2 inhibition in the prevention or reduction of oxidative stress conditions has been the subject of several studies over the last decade .
17-1	2984-2993	Exploring	_	_	_	_
17-2	2994-2997	the	abstract[153]	new[153]	_	_
17-3	2998-3002	role	abstract[153]	new[153]	_	_
17-4	3003-3005	of	abstract[153]	new[153]	_	_
17-5	3006-3011	SGLT2	abstract[153]|substance|abstract[155]	new[153]|new|new[155]	_	_
17-6	3012-3022	inhibition	abstract[153]|abstract[155]	new[153]|new[155]	_	_
17-7	3023-3025	in	abstract[153]	new[153]	_	_
17-8	3026-3029	the	abstract[153]|abstract[156]	new[153]|new[156]	_	_
17-9	3030-3040	prevention	abstract[153]|abstract[156]	new[153]|new[156]	_	_
17-10	3041-3043	or	abstract[153]	new[153]	_	_
17-11	3044-3053	reduction	abstract[153]|abstract[157]	new[153]|new[157]	coref	19-11[177_157]
17-12	3054-3056	of	abstract[153]|abstract[157]	new[153]|new[157]	_	_
17-13	3057-3066	oxidative	abstract[153]|abstract[157]|abstract[158]|abstract[159]	new[153]|new[157]|giv[158]|new[159]	coref	18-16[168_158]
17-14	3067-3073	stress	abstract[153]|abstract[157]|abstract[158]|abstract[159]	new[153]|new[157]|giv[158]|new[159]	_	_
17-15	3074-3084	conditions	abstract[153]|abstract[157]|abstract[159]	new[153]|new[157]|new[159]	_	_
17-16	3085-3088	has	_	_	_	_
17-17	3089-3093	been	_	_	_	_
17-18	3094-3097	the	object[160]	new[160]	_	_
17-19	3098-3105	subject	object[160]	new[160]	_	_
17-20	3106-3108	of	object[160]	new[160]	_	_
17-21	3109-3116	several	object[160]|abstract[161]	new[160]|giv[161]	coref	18-6[164_161]
17-22	3117-3124	studies	object[160]|abstract[161]	new[160]|giv[161]	_	_
17-23	3125-3129	over	object[160]	new[160]	_	_
17-24	3130-3133	the	object[160]|time[162]	new[160]|new[162]	_	_
17-25	3134-3138	last	object[160]|time[162]	new[160]|new[162]	_	_
17-26	3139-3145	decade	object[160]|time[162]	new[160]|new[162]	_	_
17-27	3146-3147	.	_	_	_	_

#Text=However , to date , most of the studies evaluating the effect of iSGLT2 on oxidative stress have been performed in animal models .
18-1	3148-3155	However	_	_	_	_
18-2	3156-3157	,	_	_	_	_
18-3	3158-3160	to	_	_	_	_
18-4	3161-3165	date	time	new	_	_
18-5	3166-3167	,	_	_	_	_
18-6	3168-3172	most	abstract[164]	giv[164]	coref	23-7[207_164]
18-7	3173-3175	of	abstract[164]	giv[164]	_	_
18-8	3176-3179	the	abstract[164]	giv[164]	_	_
18-9	3180-3187	studies	abstract[164]	giv[164]	_	_
18-10	3188-3198	evaluating	abstract[164]	giv[164]	_	_
18-11	3199-3202	the	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
18-12	3203-3209	effect	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
18-13	3210-3212	of	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
18-14	3213-3219	iSGLT2	abstract[164]|abstract[165]|abstract	giv[164]|giv[165]|giv	coref	19-8
18-15	3220-3222	on	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
18-16	3223-3232	oxidative	abstract[164]|abstract[165]|abstract|abstract[168]	giv[164]|giv[165]|giv|giv[168]	_	_
18-17	3233-3239	stress	abstract[164]|abstract[165]|abstract[168]	giv[164]|giv[165]|giv[168]	_	_
18-18	3240-3244	have	_	_	_	_
18-19	3245-3249	been	_	_	_	_
18-20	3250-3259	performed	_	_	_	_
18-21	3260-3262	in	_	_	_	_
18-22	3263-3269	animal	animal|abstract[170]	new|new[170]	coref	23-10[209_170]
18-23	3270-3276	models	abstract[170]	new[170]	_	_
18-24	3277-3278	.	_	_	_	_

#Text=Our data demonstrate that T2D patients receiving iSGLT2 treatment undergo a reduction in mitochondrial superoxide production in parallel to an increase in glutathione content , and markedly so after 24 weeks of treatment .
19-1	3279-3282	Our	person|abstract[172]	giv|new[172]	ana	23-1
19-2	3283-3287	data	abstract[172]	new[172]	_	_
19-3	3288-3299	demonstrate	_	_	_	_
19-4	3300-3304	that	_	_	_	_
19-5	3305-3308	T2D	abstract|person[174]	giv|giv[174]	coref	23-13
19-6	3309-3317	patients	person[174]	giv[174]	_	_
19-7	3318-3327	receiving	person[174]	giv[174]	_	_
19-8	3328-3334	iSGLT2	person[174]|abstract|abstract[176]	giv[174]|giv|giv[176]	coref|coref	19-33[0_176]|24-3
19-9	3335-3344	treatment	person[174]|abstract[176]	giv[174]|giv[176]	_	_
19-10	3345-3352	undergo	_	_	_	_
19-11	3353-3354	a	abstract[177]	giv[177]	_	_
19-12	3355-3364	reduction	abstract[177]	giv[177]	_	_
19-13	3365-3367	in	abstract[177]	giv[177]	_	_
19-14	3368-3381	mitochondrial	abstract[177]|abstract[179]	giv[177]|giv[179]	_	_
19-15	3382-3392	superoxide	abstract[177]|substance|abstract[179]	giv[177]|giv|giv[179]	coref	24-18
19-16	3393-3403	production	abstract[177]|abstract[179]	giv[177]|giv[179]	_	_
19-17	3404-3406	in	abstract[177]	giv[177]	_	_
19-18	3407-3415	parallel	abstract[177]	giv[177]	_	_
19-19	3416-3418	to	abstract[177]	giv[177]	_	_
19-20	3419-3421	an	abstract[177]|event[180]	giv[177]|new[180]	_	_
19-21	3422-3430	increase	abstract[177]|event[180]	giv[177]|new[180]	_	_
19-22	3431-3433	in	abstract[177]|event[180]	giv[177]|new[180]	_	_
19-23	3434-3445	glutathione	abstract[177]|event[180]|abstract|abstract[182]	giv[177]|new[180]|new|new[182]	ana	20-1[0_182]
19-24	3446-3453	content	abstract[177]|event[180]|abstract[182]	giv[177]|new[180]|new[182]	_	_
19-25	3454-3455	,	_	_	_	_
19-26	3456-3459	and	_	_	_	_
19-27	3460-3468	markedly	_	_	_	_
19-28	3469-3471	so	_	_	_	_
19-29	3472-3477	after	_	_	_	_
19-30	3478-3480	24	time[183]	new[183]	_	_
19-31	3481-3486	weeks	time[183]	new[183]	_	_
19-32	3487-3489	of	time[183]	new[183]	_	_
19-33	3490-3499	treatment	time[183]|abstract	new[183]|giv	coref	21-13[197_0]
19-34	3500-3501	.	_	_	_	_

#Text=This is accompanied by increased expression of the antioxidant enzymes GSR and CAT .
20-1	3502-3506	This	abstract	giv	coref	21-6[195_0]
20-2	3507-3509	is	_	_	_	_
20-3	3510-3521	accompanied	_	_	_	_
20-4	3522-3524	by	_	_	_	_
20-5	3525-3534	increased	abstract[186]	giv[186]	coref	24-13[220_186]
20-6	3535-3545	expression	abstract[186]	giv[186]	_	_
20-7	3546-3548	of	abstract[186]	giv[186]	_	_
20-8	3549-3552	the	abstract[186]|substance[188]|abstract[189]	giv[186]|giv[188]|new[189]	_	_
20-9	3553-3564	antioxidant	abstract[186]|abstract|substance[188]|abstract[189]	giv[186]|giv|giv[188]|new[189]	_	_
20-10	3565-3572	enzymes	abstract[186]|substance[188]|abstract[189]	giv[186]|giv[188]|new[189]	_	_
20-11	3573-3576	GSR	abstract[186]|abstract[189]	giv[186]|new[189]	_	_
20-12	3577-3580	and	abstract[186]	giv[186]	_	_
20-13	3581-3584	CAT	abstract[186]|object	giv[186]|new	coref	24-21
20-14	3585-3586	.	_	_	_	_

#Text=However , no changes in plasma protein carbonyl content were observed with empagliflozin treatment at these time-points .
21-1	3587-3594	However	_	_	_	_
21-2	3595-3596	,	_	_	_	_
21-3	3597-3599	no	abstract[191]	giv[191]	_	_
21-4	3600-3607	changes	abstract[191]	giv[191]	_	_
21-5	3608-3610	in	abstract[191]	giv[191]	_	_
21-6	3611-3617	plasma	abstract[191]|abstract|abstract[195]	giv[191]|giv|giv[195]	coref	23-17[212_195]
21-7	3618-3625	protein	abstract[191]|substance|abstract[195]	giv[191]|new|giv[195]	_	_
21-8	3626-3634	carbonyl	abstract[191]|substance|abstract[195]	giv[191]|new|giv[195]	_	_
21-9	3635-3642	content	abstract[191]|abstract[195]	giv[191]|giv[195]	_	_
21-10	3643-3647	were	_	_	_	_
21-11	3648-3656	observed	_	_	_	_
21-12	3657-3661	with	_	_	_	_
21-13	3662-3675	empagliflozin	substance|abstract[197]	giv|giv[197]	ana|coref	22-2[0_197]|22-15
21-14	3676-3685	treatment	abstract[197]	giv[197]	_	_
21-15	3686-3688	at	_	_	_	_
21-16	3689-3694	these	time[198]	new[198]	_	_
21-17	3695-3706	time-points	time[198]	new[198]	_	_
21-18	3707-3708	.	_	_	_	_

#Text=Whether this could be due to the small sample size or would require long-term empagliflozin treatment needs to be addressed in future research .
22-1	3709-3716	Whether	_	_	_	_
22-2	3717-3721	this	abstract	giv	coref	22-14[203_0]
22-3	3722-3727	could	_	_	_	_
22-4	3728-3730	be	_	_	_	_
22-5	3731-3734	due	_	_	_	_
22-6	3735-3737	to	_	_	_	_
22-7	3738-3741	the	abstract[201]	new[201]	_	_
22-8	3742-3747	small	abstract[201]	new[201]	_	_
22-9	3748-3754	sample	object|abstract[201]	new|new[201]	_	_
22-10	3755-3759	size	abstract[201]	new[201]	_	_
22-11	3760-3762	or	_	_	_	_
22-12	3763-3768	would	_	_	_	_
22-13	3769-3776	require	_	_	_	_
22-14	3777-3786	long-term	abstract[203]	giv[203]	coref	24-3[216_203]
22-15	3787-3800	empagliflozin	substance|abstract[203]	giv|giv[203]	_	_
22-16	3801-3810	treatment	abstract[203]	giv[203]	_	_
22-17	3811-3816	needs	_	_	_	_
22-18	3817-3819	to	_	_	_	_
22-19	3820-3822	be	_	_	_	_
22-20	3823-3832	addressed	_	_	_	_
22-21	3833-3835	in	_	_	_	_
22-22	3836-3842	future	abstract[204]	new[204]	_	_
22-23	3843-3851	research	abstract[204]	new[204]	_	_
22-24	3852-3853	.	_	_	_	_

#Text=Our findings are in accordance with previous studies in rat models of T2D , in which increased antioxidant enzyme content and activity in renal tissues has been reported .
23-1	3854-3857	Our	person|abstract[206]	giv|new[206]	_	_
23-2	3858-3866	findings	abstract[206]	new[206]	_	_
23-3	3867-3870	are	_	_	_	_
23-4	3871-3873	in	_	_	_	_
23-5	3874-3884	accordance	_	_	_	_
23-6	3885-3889	with	_	_	_	_
23-7	3890-3898	previous	abstract[207]	giv[207]	_	_
23-8	3899-3906	studies	abstract[207]	giv[207]	_	_
23-9	3907-3909	in	abstract[207]	giv[207]	_	_
23-10	3910-3913	rat	abstract[207]|animal|abstract[209]	giv[207]|new|giv[209]	_	_
23-11	3914-3920	models	abstract[207]|abstract[209]	giv[207]|giv[209]	_	_
23-12	3921-3923	of	abstract[207]|abstract[209]	giv[207]|giv[209]	_	_
23-13	3924-3927	T2D	abstract[207]|abstract[209]|abstract	giv[207]|giv[209]|giv	_	_
23-14	3928-3929	,	abstract[207]	giv[207]	_	_
23-15	3930-3932	in	abstract[207]	giv[207]	_	_
23-16	3933-3938	which	abstract[207]	giv[207]	_	_
23-17	3939-3948	increased	abstract[207]|abstract[212]	giv[207]|giv[212]	_	_
23-18	3949-3960	antioxidant	abstract[207]|abstract[212]	giv[207]|giv[212]	_	_
23-19	3961-3967	enzyme	abstract[207]|substance|abstract[212]	giv[207]|new|giv[212]	_	_
23-20	3968-3975	content	abstract[207]|abstract[212]	giv[207]|giv[212]	_	_
23-21	3976-3979	and	abstract[207]	giv[207]	_	_
23-22	3980-3988	activity	abstract[207]|abstract[213]	giv[207]|giv[213]	_	_
23-23	3989-3991	in	abstract[207]|abstract[213]	giv[207]|giv[213]	_	_
23-24	3992-3997	renal	abstract[207]|abstract[213]|object[214]	giv[207]|giv[213]|new[214]	_	_
23-25	3998-4005	tissues	abstract[207]|abstract[213]|object[214]	giv[207]|giv[213]|new[214]	_	_
23-26	4006-4009	has	abstract[207]	giv[207]	_	_
23-27	4010-4014	been	abstract[207]	giv[207]	_	_
23-28	4015-4023	reported	abstract[207]	giv[207]	_	_
23-29	4024-4025	.	_	_	_	_

#Text=Furthermore , iSGLT2 treatment in diabetic mice has been shown to induce antioxidant gene expression ( manganese-dependent superoxide dismutase and CAT ) in adipose tissue and muscle .
24-1	4026-4037	Furthermore	_	_	_	_
24-2	4038-4039	,	_	_	_	_
24-3	4040-4046	iSGLT2	abstract|abstract[216]	giv|giv[216]	_	_
24-4	4047-4056	treatment	abstract[216]	giv[216]	_	_
24-5	4057-4059	in	abstract[216]	giv[216]	_	_
24-6	4060-4068	diabetic	abstract[216]|animal[217]	giv[216]|new[217]	_	_
24-7	4069-4073	mice	abstract[216]|animal[217]	giv[216]|new[217]	_	_
24-8	4074-4077	has	_	_	_	_
24-9	4078-4082	been	_	_	_	_
24-10	4083-4088	shown	_	_	_	_
24-11	4089-4091	to	_	_	_	_
24-12	4092-4098	induce	_	_	_	_
24-13	4099-4110	antioxidant	person|abstract[220]	new|giv[220]	appos	24-17[223_220]
24-14	4111-4115	gene	abstract|abstract[220]	new|giv[220]	_	_
24-15	4116-4126	expression	abstract[220]	giv[220]	_	_
24-16	4127-4128	(	_	_	_	_
24-17	4129-4148	manganese-dependent	substance[222]|abstract[223]	new[222]|giv[223]	_	_
24-18	4149-4159	superoxide	substance|substance[222]|abstract[223]	giv|new[222]|giv[223]	_	_
24-19	4160-4169	dismutase	substance[222]|abstract[223]	new[222]|giv[223]	_	_
24-20	4170-4173	and	abstract[223]	giv[223]	_	_
24-21	4174-4177	CAT	abstract[223]|object	giv[223]|giv	_	_
24-22	4178-4179	)	_	_	_	_
24-23	4180-4182	in	_	_	_	_
24-24	4183-4190	adipose	abstract|object[226]	new|giv[226]	_	_
24-25	4191-4197	tissue	object[226]	giv[226]	_	_
24-26	4198-4201	and	_	_	_	_
24-27	4202-4208	muscle	object	new	_	_
24-28	4209-4210	.	_	_	_	_
